Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27132696

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Haematol
Publication date
2016 May
First author
Ferreri AJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2016 May;3(5):e206-7. doi: 10.1016/S2352-3026(16)30021-7.
    note
    Source null
    related pmid
    27132691
    relationship
    Comment in

Authors and identifiers

  1. name
    Ferreri AJ
    type
    Author
  2. name
    Cwynarski K
    type
    Author
  3. name
    Pulczynski E
    type
    Author
  4. name
    Ponzoni M
    type
    Author
  5. name
    Deckert M
    type
    Author
  6. name
    Politi LS
    type
    Author
  7. name
    Torri V
    type
    Author
  8. name
    Fox CP
    type
    Author
  9. name
    Rosée PL
    type
    Author
  10. name
    Schorb E
    type
    Author
  11. name
    Ambrosetti A
    type
    Author
  12. name
    Roth A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ferreri AJ
    type
    Author
  2. name
    Cwynarski K
    type
    Author
  3. name
    Pulczynski E
    type
    Author
  4. name
    Ponzoni M
    type
    Author
  5. name
    Deckert M
    type
    Author
  6. name
    Politi LS
    type
    Author
  7. name
    Torri V
    type
    Author
  8. name
    Fox CP
    type
    Author
  9. name
    Rosée PL
    type
    Author
  10. name
    Schorb E
    type
    Author
  11. name
    Ambrosetti A
    type
    Author
  12. name
    Roth A
    type
    Author
bibliography ids
  1. nci-bib-3dcab8e8f80afd6b8ef1075f
book metadata
content sha256
a6a03632e8b92625f15da43c8bb57d6803c91b48853163c96e30f35d9a357444
document type
citation
dois
  1. 10.1016/S2352-3026(16)00036-3
electronic publication date
display
2016 Apr 6
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27132696
immutable id
pubmed:27132696@a6a03632e8b92625f15da43c8bb57d6803c91b48853163c96e30f35d9a357444
journal
abbreviation
Lancet Haematol
issn electronic
2352-3026
issn print
Source null
issue
5
name
The Lancet. Haematology
nlm unique id
101643584
pages
e217-27
volume
3
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2016 May;3(5):e206-7. doi: 10.1016/S2352-3026(16)30021-7.
    note
    Source null
    related pmid
    27132691
    relationship
    Comment in
outcomes validated
false
pmid
27132696
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
71de1110f6d36a17fbf8aaf9ec84c5a71290bf5e586431e5a61c7c0854f4fcb8
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 May
precision
month
year
2016
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27132696/
title
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

Preserved source evidence · Not medical advice